

MICRO-X RECEIVES \$6.4 MILLION – R&D TAX INCENTIVE

Adelaide, Australia, 5 December 2024: Australian hi-tech company Micro-X Ltd (ASX:MX1) (**Micro-X** or the **Company**), a leader in cold cathode X-ray technology for health and security markets globally, is pleased to announce that it has received a Research & Development (R&D) Tax Incentive, net of income tax payable, of \$5.83 million for the financial year ended 30 June 2024 and an additional \$0.58 million relating to an amendment to the Company's FY22 R&D tax incentive. The total of \$6.41 million received is consistent with the Company's previous guidance.

The cash rebate from the Australian Tax Office is related to the expenditure on eligible Australian R&D activities conducted during the 2023/2024 financial year and 2021/2022 financial year respectively.

The Company previously accessed \$4.57 million using an advance funding facility which is repaid as part of the receipt.

This ASX announcement is authorised by Kingsley Hall, Company Secretary of Micro-X.

– ENDS –

About Micro-X

Micro-X Limited (the Company) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control emitters with this technology enables x-ray products with significant reduction in size, weight, and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

Micro-X's product portfolio spans four, high margin, product applications in health and security. The first mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military and veterinary applications and the Argus X-ray Camera for security and defence is now commercially available. The US Department of Homeland Security has contracted Micro-X to design a next-generation Airport security checkpoint. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances, is being developed with funding from the Australian Government's Medical Research Future Fund.

For more information visit: www.micro-x.com

Contacts

Micro-X Limited	Investor Enquiries
Kingsley Hall , Chief Executive Officer Rebecca Puddy , Head of Corporate Communications Tel: +61 8 7099 3966 Email: media@micro-x.com	David Allen/John Granger Hawesbury Partners Tel: +61 2 9103 9494 Email: dallen@hawkesburypartners.com jgranger@hawkesburypartners.com